Edition:
United Kingdom

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

4.87USD
23 Apr 2018
Change (% chg)

$-0.36 (-6.88%)
Prev Close
$5.23
Open
$5.20
Day's High
$5.31
Day's Low
$4.71
Volume
56,764
Avg. Vol
49,969
52-wk High
$14.09
52-wk Low
$4.39

Select another date:

Tue, Mar 27 2018

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

BRIEF-Nabriva Appoints Jennifer Schranz As Chief Medical Officer

* NABRIVA THERAPEUTICS APPOINTS JENNIFER SCHRANZ, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Nabriva Therapeutics PLC Files For Mixed Shelf Of Upto $225 Million - SEC Filing

* NABRIVA THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source text (http://bit.ly/2HEW5CR) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Nabriva Therapeutics ‍had $86.9 Mln In Cash, Cash Equivalents as Of Dec 31

* NABRIVA THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

Select another date: